Work

Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw383.40

Authors: J. Yang, Y. Cheng, H. Murakami, P.-C. Yang, J. He, K. Nakagawa, J.H. Kang, J.-H. Kim, R. Hozak, T. Nguyen, X. Wang, S. Enatsu, T. Puri, M. Orlando

Institutions: National Taiwan University Hospital, Jilin Province Tumor Hospital, Shizuoka Cancer Center, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Kindai University, Catholic University of Korea, CHA University Bundang Medical Center, CHA University, Eli Lilly (United States), Lilly (China), Eli Lilly (Japan), Eli Lilly (India)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2588300980

FWCI: 0.299

Cites:

Cited by: 3

Related to: 10